International Patent: MULTISPECIFIC ANTIBODY TARGETING TROP2 AND PD-L1, AND ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF

GENEVA, Oct. 30 -- HELIXON BIOTECHNOLOGY (SUZHOU) CO., LTD filed a patent application (CN2026/092679) for “MULTISPECIFIC ANTIBODY TARGETING TROP2 AND PD-L1, AND ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF”. With publication no. WO/2026/223772, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: C07K 16/46

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....